Gold Standard Diagnostics introduces ThunderBolt automated diagnostics platform
12 August 2010
Gold Standard Diagnostics, Corp. (GSD), has introduced the ThunderBolt platform, the company’s first automated instrumentation offering for clinical and hospital laboratories.
The ThunderBolt platform will provide laboratory customers with a single hardware solution that can utilize multiple diagnostics technologies such as EIA, chemiluminescence and multiplexing.
The inaugural product of the ThunderBolt platform is an EIA (enzyme immunoassay) processor, with a completely open software design capable of programming virtually any EIA test. EIA tests are widely used to detect and quantify substances such as peptides, proteins, antibodies and hormones, and to diagnose diseases and conditions including infections, cancer, metabolic disorders, allergies and autoimmune diseases.
In a single, easily configured run, the flexible ThunderBolt EIA processor can process multiple microtiter plates, while also running up to eight different simultaneous assays. With an onboard reader, the fully automated EIA processor offers a true “walkaway” solution for labs of any size.
The compact design takes up less than half the workspace of similar EIA automated processors on the market. Cost-effective operation makes the ThunderBolt suitable for larger clinical laboratories, while it also provides the customizable capabilities needed in hospital or research laboratories.
“The ThunderBolt platform represents a true innovation in automated diagnostics instrumentation and is the culmination of nearly 20 years of feedback from laboratory customers around the world,” says John Griffiths, president and CEO of Gold Standard Diagnostics. “By understanding what customers really need, we have been able to build a product that’s the right blend of power, flexibility and ease of use, all at a competitive price.”